Leslie interview on ******
A few comment/take aways
'Phenominal early data'
Data pivot point through adaptive trial design means they have data to discuss with big pharma to 'expeditiously' market or partner to get drug to patients as soon as possible.
Emboldens B cell space - high degree of confidence and monopoly.
When asked about discussions with big pharma and market sensitivity, Leslie said it was like a marriage and you have to find the right fit!
So I take that as saying there are several interested 'suitors' on 'bended knee' using the same analogy.
Leslie interview on ******A few comment/take...
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |